Recursion director sells 40,000 shares under 10b5-1 plan

RECURSION PHARMACEUTICALS, INC. director Blake Borgeson reported an open-market sale of Class A common stock.

Rhea-AI Filing Summary

RECURSION PHARMACEUTICALS, INC. director Blake Borgeson reported an open-market sale of Class A common stock. On July 7, 2026, he sold 40,000 shares at a weighted average price of about $3.96 per share. After this transaction, he directly holds 6,218,287 shares of the company.

The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on August 31, 2025. The shares were sold in multiple trades at prices ranging from $3.95 to $4.00, with the reported price reflecting the weighted average sale price.

Insider Trade Summary 10b5-1

Net Seller: 40,000 shares

Net Sell 1 txn

Insider Borgeson Blake

Role Director

Sold 40,000 shs ($159K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	40,000	$3.9625	$159K

Holdings After Transaction: Class A Common Stock — 6,218,287 shares (Direct)

Footnotes (2)

1. F1. This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025.
2. F2. This transaction was executed in multiple trades at prices ranging from $3.95 to $4.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Key Figures

Shares sold: 40,000 shares Weighted average sale price: $3.9625 per share Post-transaction holdings: 6,218,287 shares +2 more

5 metrics

Shares sold 40,000 shares Class A Common Stock sold on July 7, 2026

Weighted average sale price $3.9625 per share Average price for 40,000 shares sold

Post-transaction holdings 6,218,287 shares Direct ownership after July 7, 2026 sale

Sale price range $3.95–$4.00 per share Range of individual trade prices for the sale

Trading plan adoption date August 31, 2025 Rule 10b5-1 trading plan adoption by reporting person

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, open-market sale, Class A Common Stock

4 terms

Rule 10b5-1 trading plan regulatory

"This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Class A Common Stock financial

"security_title: "Class A Common Stock""

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did RXRX director Blake Borgeson report?

Blake Borgeson reported an open-market sale of 40,000 shares of RECURSION PHARMACEUTICALS Class A common stock. The transaction occurred on July 7, 2026, and was disclosed as a routine Form 4 insider filing with the Securities and Exchange Commission.

At what price did Blake Borgeson sell RXRX shares in this Form 4?

He sold 40,000 RXRX shares at a weighted average price of approximately $3.9625 per share. The trades were executed in multiple lots, with individual prices ranging from $3.95 to $4.00 during the transaction.

How many RXRX shares does Blake Borgeson hold after this transaction?

After selling 40,000 shares, Blake Borgeson directly holds 6,218,287 shares of RECURSION PHARMACEUTICALS Class A common stock. This post-transaction ownership figure is reported in the Form 4 as his direct holding balance following the sale.

Was the RXRX insider sale by Blake Borgeson under a Rule 10b5-1 plan?

Yes. The filing states the sale was made pursuant to a Rule 10b5-1 trading plan adopted on August 31, 2025. Such plans allow pre-scheduled trades, helping insiders diversify holdings while reducing concerns about trading on nonpublic information.

What does the price range in Blake Borgeson’s RXRX sale mean?

The filing explains the 40,000 RXRX shares were sold in multiple trades between $3.95 and $4.00 per share. The reported $3.9625 figure is the weighted average sale price across all those individual trade executions.

What type of security did Blake Borgeson sell in this RXRX Form 4?

He sold shares of RECURSION PHARMACEUTICALS Class A common stock, categorized as a non-derivative security. The Form 4 does not list any related option exercises or derivative transactions alongside this reported sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/09/2026 - 06:04 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Borgeson Blake

(Last) (First) (Middle)

C/O RECURSION PHARMACEUTICALS

41 S. RIO GRANDE STREET

(Street)

SALT LAKE CITY UTAH 84101

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	07/07/2026		S(1)		40,000	D	$3.9625(2)	6,218,287	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025.

2. This transaction was executed in multiple trades at prices ranging from $3.95 to $4.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Remarks:

	/s/Jonathan Golightly, attorney-in-fact	07/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)